What question did this study set out to answer?

This study aims to evaluate clinical outcomes and relapse risk in patients with peripheral T-cell lymphoma who achieved complete response after initial therapy.

December 8, 2025Blood

Continued risk of relapse in peripheral T-cell lymphoma even in patients who achieved complete response after initial therapy

View Full Paper

Ask AI

Bookmark

Authors

YSYuko ShirouchiTohoku University YMYuka MoritaUniversity of Toyama DMDai MaruyamaKeio University

Discussion

Member takes

Overview

Retrospective analysis reveals relapse rates in peripheral T-cell lymphoma patients achieving complete response, suggesting ongoing monitoring is crucial.

Key Points

This study aims to evaluate clinical outcomes and relapse risk in patients with peripheral T-cell lymphoma who achieved complete response after initial therapy.
Retrospective analysis of patients with peripheral T-cell lymphoma who received initial therapy without autologous stem cell transplantation.
A total of 102 patients were followed, with outcomes analyzed based on therapy received.
Cumulative relapse rates and survival metrics were calculated for patients achieving complete response.
Thirty-five of 59 patients (59%) who achieved complete response experienced relapse, indicating a high risk.
The median progression-free survival for those who relapsed was 9 months post-relapse.
The median overall survival post-relapse was 29 months, demonstrating the need for improved treatment strategies.

Cite This Study

Shirouchi et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d73a https://doi.org/10.1182/blood-2025-7152

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

Continued risk of relapse in peripheral T-cell lymphoma even in patients who achieved complete response after initial therapy

View Full Paper

Ask AI

Bookmark

Authors

YSYuko ShirouchiTohoku University YMYuka MoritaUniversity of Toyama DMDai MaruyamaKeio University

Discussion

Member takes

Overview

Retrospective analysis reveals relapse rates in peripheral T-cell lymphoma patients achieving complete response, suggesting ongoing monitoring is crucial.

Key Points

This study aims to evaluate clinical outcomes and relapse risk in patients with peripheral T-cell lymphoma who achieved complete response after initial therapy.
Retrospective analysis of patients with peripheral T-cell lymphoma who received initial therapy without autologous stem cell transplantation.
A total of 102 patients were followed, with outcomes analyzed based on therapy received.
Cumulative relapse rates and survival metrics were calculated for patients achieving complete response.
Thirty-five of 59 patients (59%) who achieved complete response experienced relapse, indicating a high risk.
The median progression-free survival for those who relapsed was 9 months post-relapse.
The median overall survival post-relapse was 29 months, demonstrating the need for improved treatment strategies.

Cite This Study

Shirouchi et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d73a https://doi.org/10.1182/blood-2025-7152

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark